Developer docs
API playgroundTry for free, no card

Search company profiles

Aptissen

Full company profile

uuid0009plc

Namestring
Aptissen
Legal namestring
APTISSEN SA
Websiteurl
aptissen.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Aptissen SA is a Swiss musculoskeletal specialist founded in 2013 as a spin-off from Anteis, headquartered in Plan-les-Ouates, Switzerland. The company develops and commercializes orthobiologic solutions for joint disorders, with two core commercial products: Synolis VA, a patented injectable viscosupplement gel combining Hyaluronic Acid and Sorbitol (an antioxidant) available in two concentrations (40mg HA/80mg Sorbitol and 80mg HA/160mg Sorbitol), and Cartylis, a drinkable collagen-based food supplement with vitamins C, D, E, and selenium designed to support joint health. The underlying technology leverages the proprietary HA-Sorbitol combination to create viscoelastic properties similar to healthy young synovial fluid, producing fast pain relief (within one week) with effects lasting up to 6 months based on published clinical evidence.

The company operates a B2B distribution model through five wholly-owned subsidiaries (Italy, Poland, France, Germany, Brazil) and a worldwide distributor network covering more than 50 countries including Switzerland, Canada, Mexico, UAE, Singapore, and Malaysia. Revenue is generated through one-time sales of medical devices to physicians and healthcare providers (primary segment) and consumer-facing nutritional supplements via distributor networks, with pricing not publicly disclosed. Aptissen holds ISO 13485:2016 (2018), CE marking (2019), and MDSAP certification (2020), enabling regulatory access across Europe, Canada, and Brazil. The company's clinical evidence base includes 20+ peer-reviewed publications and quantified outcomes such as 61.8% pain relief and 78.8% OMERACT-OARSI responder rate at 6 months.

Aptissen is actively investing in pipeline expansion (RID-02 for osteoarthritis, TID-03 for tendinopathies, FS02 for osteochondrosis), physician education through Aptissen Academy, and congress-based marketing across major orthopedic and sports medicine events. The company is privately held with 11-50 employees and has completed one disclosed funding round (FONGIT, June 2014).

Short descriptiontext

Aptissen is a Swiss musculoskeletal specialist that develops and distributes orthobiologic solutions, including the patented Synolis VA injectable viscosupplement and Cartylis collagen supplement, sold to physicians, healthcare providers, and consumers across 50+ countries via direct subsidiaries and distributor networks.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersPlan-les-ouates, Switzerland
HQ citystring
Plan-les-ouates
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
orthobiologic solutions, viscosupplementation injectables, hyaluronic acid treatments, joint health supplements, osteoarthritis medical devices
Industry2 codes
PRIMARYHLAIAAAN
Pain Management & Anesthesiology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYAFAJAKAK
Condition-Specific Bioactives (Glucosamine/Chondroitin, Plant Sterols, Melatonin, Lutein/Zeaxanthin)
Agriculture & Food Production/Food Ingredients & Additives/Nutraceutical & Functional Ingredients (Vitamins, Minerals, Omega-3s, Botanicals)
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers423450
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Orthobiologics / Medical Devices for Musculoskeletal Care
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Synolis VA Sales
TypeOne Time License
Description

Sale of patented injectable viscosupplement gel for osteoarthritis treatment. Distributed through direct subsidiaries and worldwide distributor network. Available in two formulations (40/80 and 80/160 HA/Sorbitol).

aptissen.com
2Cartylis Food Supplement Sales
TypeOne Time License
Description

Sale of drinkable food supplement containing collagen, vitamins and selenium for joint health. Sold in packs of 28 vials (25ml each).

aptissen.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Synolis VA
Description

Patented injectable viscosupplement gel containing Hyaluronic Acid and Sorbitol for osteoarthritis treatment

aptissen.com
+2 more records
Core offering1 text field

Aptissen develops and commercializes orthobiologic solutions for musculoskeletal conditions, primarily Synolis VA, a patented injectable viscosupplement gel combining Hyaluronic Acid and Sorbitol for intra-articular treatment of osteoarthritis. The company also offers Cartylis, a drinkable food supplement containing collagen, vitamins and selenium to support joint health, and maintains a pipeline of medical devices and supplements for osteoarthritis, tendinopathies and osteochondrosis. Products are distributed in 50+ countries via direct subsidiaries and a worldwide distributor network targeting physicians, healthcare providers and pharmaceutical partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 61.8% pain relief at 6 months
+4 more records
Product overview1 text field

Aptissen is a Swiss musculoskeletal expert founded in 2013 that provides orthobiologic solutions for joint disorders. The company's product portfolio centers on two main commercial offerings: Synolis VA (a viscosupplement injectable gel combining hyaluronic acid and sorbitol, available in two strengths: 40/80 and 80/160 formulations) for intra-articular treatment of osteoarthritis, and Cartylis (a drinkable collagen-based food supplement with vitamins and minerals for daily joint support). Products are distributed through a worldwide network spanning over 50 countries including Switzerland, France, Italy, Poland, Canada, Mexico, Brazil, UAE, Singapore, and Malaysia. The company maintains a development pipeline including medical devices RID-02 (osteoarthritis), TID-03 (tendinopathies), and nutritional supplement FS02 (osteochondrosis).

Product and service3 records
1Synolis VA 40mg HA/80mg Sorbitol
CategoryViscosupplement (injectable medical device)
Description

A patented injectable viscosupplement gel containing 40mg Hyaluronic Acid and 80mg Sorbitol, designed for intra-articular treatment of osteoarthritis. Provides fast pain relief with viscoelastic properties similar to healthy young synovial fluid and effects lasting up to 6 months. Sold to physicians and healthcare providers through distributors and direct subsidiaries.

2Synolis VA 80mg HA/160mg Sorbitol
CategoryViscosupplement (injectable medical device)
Description

A higher-dose patented injectable viscosupplement gel containing 80mg Hyaluronic Acid and 160mg Sorbitol for intra-articular treatment of osteoarthritis. Offers extended pain relief with the same antioxidant-enhanced viscoelastic properties as the 40/80 formulation, with effects lasting up to 6 months. CE-marked medical device distributed to physicians and healthcare providers.

3Cartylis
CategoryNutritional / Food Supplement
Description

A drinkable food supplement designed to boost joint health. Contains collagen, vitamin C, vitamin D, vitamin E, and selenium. Each pack contains 28 vials of 25ml with strawberry and banana flavor, intended for daily use over 12 weeks to stimulate joints and promote collagen synthesis. Distributed via the Aptissen distributor and subsidiary network.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Aptissen engages in collaborations with universities, foundations, and research institutions for scientific research support. The company emphasizes strategic partnerships in pharmacy, biotechnology, medical techniques, and research to continue providing innovative health solutions.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

The company seeks national and regional distribution partners, as well as licensing partners for products, patents, and technologies. Partners interested in joining the network can apply through regional contact forms.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Large orthopedic medical device company whose portfolio includes gel-one, an HA viscosupplement. Competes with Aptissen in viscosupplementation as part of a much broader orthopedics and sports medicine portfolio.

2Seikagaku Corporation
TypeDirect peer
Description

Japanese specialty company marketing Supartz (sodium hyaluronate) for knee OA in the US and other markets. Direct competitor in viscosupplementation with comparable positioning around purified HA injectables.

TypeDirect peer
Description

US-based specialty company commercializing HA viscosupplements (Monovisc, Orthovisc) directly competing with Synolis VA in the intra-articular osteoarthritis treatment category. Closest like-for-like competitor in product profile and indication.

TypeDirect peer
Description

Markets Durolane and Gelsyn-3, single-injection and multi-injection HA viscosupplements for knee OA, directly competing with Synolis VA. Also active in orthobiologics, an adjacent category to Aptissen's pipeline.

TypeBroad incumbent
Description

Markets Synvisc and Synvisc-One (hylan G-F 20), historically the leading viscosupplement franchise globally. As a large diversified pharma, Sanofi competes with Synolis VA across all of Aptissen's key markets but does not specialize in the orthobiologic niche.

TypeEmerging player
Description

Czech manufacturer specializing in hyaluronic acid and other biopolymers for medical, cosmetic, and supplement applications. Operates as a potential supplier/competitor at the upstream end of the HA value chain that Aptissen also serves.

TypeDirect peer
Description

Italian specialty pharma that developed Hyalgan, one of the original HA viscosupplements for OA. Directly comparable in product (HA injection for joint pain) and regional heritage (European-headquartered, similar LATAM presence).

TypeDirect peer
Description

Swiss-headquartered specialty pharma marketing Sinovial and other HA-based viscosupplements. Closely comparable in size, Swiss origin, orthobiologic focus, and channel mix targeting physicians for OA treatment.

TypeDirect peer
Description

Sells Euflexxa (1% sodium hyaluronate), a direct viscosupplement competitor to Synolis VA. Privately held Swiss-headquartered pharma with similar European distribution orientation and orthopedics focus.

10LG Chem Life Sciences
TypeDirect peer
Description

Korean life sciences arm of LG Chem that markets Hyruan and other HA viscosupplements in Asia and select global markets. Directly comparable injectable HA product and similar channel approach through local distributors.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

Integration5 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries5 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Aptissen

Orthobiologics / Medical Devices for Musculoskeletal Careaptissen.com

Aptissen is a Swiss musculoskeletal specialist that develops and distributes orthobiologic solutions, including the patented Synolis VA injectable viscosupplement and Cartylis collagen supplement, sold to physicians, healthcare providers, and consumers across 50+ countries via direct subsidiaries and distributor networks.

What Aptissen does

Aptissen SA is a Swiss musculoskeletal specialist founded in 2013 as a spin-off from Anteis, headquartered in Plan-les-Ouates, Switzerland. The company develops and commercializes orthobiologic solutions for joint disorders, with two core commercial products: Synolis VA, a patented injectable viscosupplement gel combining Hyaluronic Acid and Sorbitol (an antioxidant) available in two concentrations (40mg HA/80mg Sorbitol and 80mg HA/160mg Sorbitol), and Cartylis, a drinkable collagen-based food supplement with vitamins C, D, E, and selenium designed to support joint health. The underlying technology leverages the proprietary HA-Sorbitol combination to create viscoelastic properties similar to healthy young synovial fluid, producing fast pain relief (within one week) with effects lasting up to 6 months based on published clinical evidence.

The company operates a B2B distribution model through five wholly-owned subsidiaries (Italy, Poland, France, Germany, Brazil) and a worldwide distributor network covering more than 50 countries including Switzerland, Canada, Mexico, UAE, Singapore, and Malaysia. Revenue is generated through one-time sales of medical devices to physicians and healthcare providers (primary segment) and consumer-facing nutritional supplements via distributor networks, with pricing not publicly disclosed. Aptissen holds ISO 13485:2016 (2018), CE marking (2019), and MDSAP certification (2020), enabling regulatory access across Europe, Canada, and Brazil. The company's clinical evidence base includes 20+ peer-reviewed publications and quantified outcomes such as 61.8% pain relief and 78.8% OMERACT-OARSI responder rate at 6 months.

Aptissen is actively investing in pipeline expansion (RID-02 for osteoarthritis, TID-03 for tendinopathies, FS02 for osteochondrosis), physician education through Aptissen Academy, and congress-based marketing across major orthopedic and sports medicine events. The company is privately held with 11-50 employees and has completed one disclosed funding round (FONGIT, June 2014).

Aptissen firmographics

Firmographics
Name
Aptissen
Legal name
APTISSEN SA
Website
https://aptissen.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
51–100 employees
Short description
Aptissen is a Swiss musculoskeletal specialist that develops and distributes orthobiologic solutions, including the patented Synolis VA injectable viscosupplement and Cartylis collagen supplement, sold to physicians, healthcare providers, and consumers across 50+ countries via direct subsidiaries and distributor networks.
Ownership category
akta.pro rank

Aptissen industry classification

Industry
Product category
Orthobiologics / Medical Devices for Musculoskeletal Care
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers (423450)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAIAAAN
Pain Management & Anesthesiology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYAFAJAKAK
Condition-Specific Bioactives (Glucosamine/Chondroitin, Plant Sterols, Melatonin, Lutein/Zeaxanthin)
Agriculture & Food Production/Food Ingredients & Additives/Nutraceutical & Functional Ingredients (Vitamins, Minerals, Omega-3s, Botanicals)

Keywords

  • Orthobiologic solutions
  • Viscosupplementation injectables
  • Hyaluronic acid treatments
  • Joint health supplements
  • Osteoarthritis medical devices

Where Aptissen is headquartered

Location

Headquarters

HQ city
Plan-les-ouates
HQ country
Switzerland
HQ region
Europe

Offices6 records

Markets served

Aptissen business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain, Others

Revenue model

  1. Synolis VA Sales: Sale of patented injectable viscosupplement gel for osteoarthritis treatment. Distributed through direct subsidiaries and worldwide distributor network. Available in two formulations (40/80 and 80/160 HA/Sorbitol).
  2. Cartylis Food Supplement Sales: Sale of drinkable food supplement containing collagen, vitamins and selenium for joint health. Sold in packs of 28 vials (25ml each).

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Aptissen product offering

Product offering

Core offering

Aptissen develops and commercializes orthobiologic solutions for musculoskeletal conditions, primarily Synolis VA, a patented injectable viscosupplement gel combining Hyaluronic Acid and Sorbitol for intra-articular treatment of osteoarthritis. The company also offers Cartylis, a drinkable food supplement containing collagen, vitamins and selenium to support joint health, and maintains a pipeline of medical devices and supplements for osteoarthritis, tendinopathies and osteochondrosis. Products are distributed in 50+ countries via direct subsidiaries and a worldwide distributor network targeting physicians, healthcare providers and pharmaceutical partners.

Product overview

Aptissen is a Swiss musculoskeletal expert founded in 2013 that provides orthobiologic solutions for joint disorders. The company's product portfolio centers on two main commercial offerings: Synolis VA (a viscosupplement injectable gel combining hyaluronic acid and sorbitol, available in two strengths: 40/80 and 80/160 formulations) for intra-articular treatment of osteoarthritis, and Cartylis (a drinkable collagen-based food supplement with vitamins and minerals for daily joint support). Products are distributed through a worldwide network spanning over 50 countries including Switzerland, France, Italy, Poland, Canada, Mexico, Brazil, UAE, Singapore, and Malaysia. The company maintains a development pipeline including medical devices RID-02 (osteoarthritis), TID-03 (tendinopathies), and nutritional supplement FS02 (osteochondrosis).

Differentiator

Problem solved

Functional benefit

Brands

  • Synolis VA: Patented injectable viscosupplement gel containing Hyaluronic Acid and Sorbitol for osteoarthritis treatment
  • Cartylis
  • Healavis

Products and services

  • Synolis VA 40mg HA/80mg Sorbitol A patented injectable viscosupplement gel containing 40mg Hyaluronic Acid and 80mg Sorbitol, designed for intra-articular treatment of osteoarthritis. Provides fast pain relief with viscoelastic properties similar to healthy young synovial fluid and effects lasting up to 6 months. Sold to physicians and healthcare providers through distributors and direct subsidiaries.
  • Synolis VA 80mg HA/160mg Sorbitol A higher-dose patented injectable viscosupplement gel containing 80mg Hyaluronic Acid and 160mg Sorbitol for intra-articular treatment of osteoarthritis. Offers extended pain relief with the same antioxidant-enhanced viscoelastic properties as the 40/80 formulation, with effects lasting up to 6 months. CE-marked medical device distributed to physicians and healthcare providers.
  • Cartylis A drinkable food supplement designed to boost joint health. Contains collagen, vitamin C, vitamin D, vitamin E, and selenium. Each pack contains 28 vials of 25ml with strawberry and banana flavor, intended for daily use over 12 weeks to stimulate joints and promote collagen synthesis. Distributed via the Aptissen distributor and subsidiary network.

Quantifiable outcome

  • 61.8% pain relief at 6 months
  • +4 more outcomes

Companies that use Aptissen

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Aptissen technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration5 records

Feature4 records

Aptissen partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Medical and Research InstitutionscoreStrategic or Co-development PartnerAptissen engages in collaborations with universities, foundations, and research institutions for scientific research support. The company emphasizes strategic partnerships in pharmacy, biotechnology, medical techniques, and research to continue providing innovative health solutions.
  • Distribution PartnerscoreChannel Partner/ Reseller/ DistributorThe company seeks national and regional distribution partners, as well as licensing partners for products, patents, and technologies. Partners interested in joining the network can apply through regional contact forms.

Scale indicators5 records

Recent moves7 records

Expansion highlights4 records

Aptissen competitors and assessment

Company assessment

Broad incumbents

  • Zimmer Biomet: Large orthopedic medical device company whose portfolio includes gel-one, an HA viscosupplement. Competes with Aptissen in viscosupplementation as part of a much broader orthopedics and sports medicine portfolio.
  • Sanofi: Markets Synvisc and Synvisc-One (hylan G-F 20), historically the leading viscosupplement franchise globally. As a large diversified pharma, Sanofi competes with Synolis VA across all of Aptissen's key markets but does not specialize in the orthobiologic niche.

Direct peers

  • Seikagaku Corporation: Japanese specialty company marketing Supartz (sodium hyaluronate) for knee OA in the US and other markets. Direct competitor in viscosupplementation with comparable positioning around purified HA injectables.
  • Anika Therapeutics: US-based specialty company commercializing HA viscosupplements (Monovisc, Orthovisc) directly competing with Synolis VA in the intra-articular osteoarthritis treatment category. Closest like-for-like competitor in product profile and indication.
  • Bioventus: Markets Durolane and Gelsyn-3, single-injection and multi-injection HA viscosupplements for knee OA, directly competing with Synolis VA. Also active in orthobiologics, an adjacent category to Aptissen's pipeline.
  • Fidia Farmaceutici: Italian specialty pharma that developed Hyalgan, one of the original HA viscosupplements for OA. Directly comparable in product (HA injection for joint pain) and regional heritage (European-headquartered, similar LATAM presence).
  • IBSA Farmaceutici: Swiss-headquartered specialty pharma marketing Sinovial and other HA-based viscosupplements. Closely comparable in size, Swiss origin, orthobiologic focus, and channel mix targeting physicians for OA treatment.
  • Ferring Pharmaceuticals: Sells Euflexxa (1% sodium hyaluronate), a direct viscosupplement competitor to Synolis VA. Privately held Swiss-headquartered pharma with similar European distribution orientation and orthopedics focus.
  • LG Chem Life Sciences: Korean life sciences arm of LG Chem that markets Hyruan and other HA viscosupplements in Asia and select global markets. Directly comparable injectable HA product and similar channel approach through local distributors.

Emerging players

  • Contipro: Czech manufacturer specializing in hyaluronic acid and other biopolymers for medical, cosmetic, and supplement applications. Operates as a potential supplier/competitor at the upstream end of the HA value chain that Aptissen also serves.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Aptissen compliance and trust

Trust signal

Compliance3 records

Aptissen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Aptissen leadership team

Management profile

Number of profiles

Profiles6 records

Aptissen subsidiaries and ownership

Company hierarchy

Subsidiaries5 records

Aptissen funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Aptissen M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aptissen

What does Aptissen do?

Aptissen develops and commercializes orthobiologic solutions for musculoskeletal conditions, primarily Synolis VA, a patented injectable viscosupplement gel combining Hyaluronic Acid and Sorbitol for intra-articular treatment of osteoarthritis. The company also offers Cartylis, a drinkable food supplement containing collagen, vitamins and selenium to support joint health, and maintains a pipeline of medical devices and supplements for osteoarthritis, tendinopathies and osteochondrosis. Products are distributed in 50+ countries via direct subsidiaries and a worldwide distributor network targeting physicians, healthcare providers and pharmaceutical partners.

Is Aptissen a public or private company?

Aptissen is a private company. It is classified as unknown and is currently operating.

When was Aptissen founded?

Aptissen was founded in 2013. It employs 51 to 100 people.

Where is Aptissen based?

Aptissen is headquartered in Plan-les-ouates, Switzerland, in the Europe region.

How does Aptissen make money?

Two revenue lines are on record. Synolis VA Sales are the primary driver. The others are cartylis Food Supplement Sales.

Who are Aptissen's main competitors?

Broad incumbents on record are Zimmer Biomet and Sanofi. Direct peers are Seikagaku Corporation, Anika Therapeutics, Bioventus, Fidia Farmaceutici, IBSA Farmaceutici, Ferring Pharmaceuticals and LG Chem Life Sciences. Contipro is listed as an emerging player.

Does Aptissen have an API?

No public API is recorded for Aptissen.

What industry is Aptissen in?

Aptissen's product category is Orthobiologics / Medical Devices for Musculoskeletal Care. Its primary akta.pro industry code is HLAIAAAN, Pain Management & Anesthesiology Pharmaceuticals, with a secondary code of AFAJAKAK, Condition-Specific Bioactives (Glucosamine/Chondroitin, Plant Sterols, Melatonin, Lutein/Zeaxanthin). Its NAICS code is 3254 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals